In 274 adults with type 2 diabetes on basal insulin, weekly cagrilintide-semaglutide (2·4 mg or 1·0 mg each) cut HbA1c by 2·33% and 2·10% vs 0·66% with placebo at 40 weeks (differences -1·68 and -1·44 points); weight fell 10-12%, no severe hypoglycaemia.
RCTn = 274
Rosenstock et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study